pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 120 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
120 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ADAURA - D5164C00001
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
AZD0780 Placebo, AZD0780
AstraZeneca AB
Heterozygous familial hypercholesterolaemia
1 trial -
AZD0780, AZD0780 Placebo
AstraZeneca AB
Hyperlipidemia, Atherosclerotic cardiovascular disease
1 trial -
AZD0780, AZD0780 placebo
AstraZeneca AB
Atherosclerotic Cardiovascular Disease
1 trial -
Anifrolumab
AstraZeneca AB
Moderate-to-severe Systemic Lupus Erythematosus (SLE)
1 trial -
Anifrolumab, Anifrolumab Placebo
AstraZeneca AB
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria
1 trial -
BaxHTN / D6970C00002
AstraZeneca AB
Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
1 trial -
Baxdrostat, Baxdrostat Placebo
AstraZeneca AB
Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
1 trial -
CROSSING
AstraZeneca AB
Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus
1 trial -
Calquence 100 mg hard capsules
AstraZeneca AB
Chronic lymphocytic leukemia
1 trial -
D0817C00098
AstraZeneca AB
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer
1 trial -
D081CC00006
AstraZeneca AB
Breast Cancer
1 trial -
D3250C00101
AstraZeneca AB
Eosinophilic Asthma
1 trial -
D3252C00002
AstraZeneca AB
Severe CRSwNP patients with asthma.
1 trial -
D3253C00001
AstraZeneca AB
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
1 trial -
D3254C00001
AstraZeneca AB
Hypereosinophilic Syndrome (HES)
1 trial -
D346BC00001
AstraZeneca AB
Cutaneous Lupus Erythematosus
1 trial -
D3614C00001
AstraZeneca AB
Triple-negative Breast Cancer
1 trial -
D3615C00001
AstraZeneca AB
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
1 trial -
D361BC00001
AstraZeneca AB
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency
1 trial -
D361EC00001
AstraZeneca AB
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
D4191C00140
AstraZeneca AB
Advanced Biliary Tract Cancers
1 trial -
D419CC00002
AstraZeneca AB
Advanced hepatocellular carcinoma (HCC)
1 trial -
D419JC00001(POTOMAC)
AstraZeneca AB
Non-muscle invasive bladder cancer
1 trial -
D4325C00010
AstraZeneca AB
Chronic Kidney Disease and High Proteinuria
1 trial -
D5086C00001
AstraZeneca AB
MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
1 trial -
D5087C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D5160C00048
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
D5162C00042
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D5169C00001 FLAURA2
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
D516AC00001
AstraZeneca AB
Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
1 trial -
D516FC00001(ADAURA2)
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
D516KC00001
AstraZeneca AB
Non squamous non-small cell lung cancer (NSCLC)
1 trial -
D516NC00001
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
D5180C00016
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
D5241C00006
AstraZeneca AB
Chronic obstructive pulmonary disease (COPD)
1 trial -
D533BC00001
AstraZeneca AB
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
D5982C00006
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
D5982C00007
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
D5982C00008
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
D5985C00002
AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)
1 trial -
D5989C00001 THARROS
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D6185C00001
AstraZeneca AB
Patients with non-small cell lung cancer (NSCLC).
1 trial -
D6402C00012
AstraZeneca AB
Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death
1 trial -
D6900C00003
AstraZeneca AB
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
1 trial -
D6972C00002
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D6972C00003
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D6973C00001
AstraZeneca AB
Prevention of Heart failure
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
120 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.